Biogen Names Viehbacher New CEO

Name Art / 10/11/2022 / Business News

[ad_1]

The veteran pharmaceutical executive takes charge of after the failed launch of Biogen’s once-promising Alzheimer’s disease drug Aduhelm.

[ad_2]

Source link

Source link

Category Business News Tag Alternative Investments BIIB Biogen Biotechnology C&E Executive News Filter C&E Industry News Filter CEO Christopher Viehbacher Content Types corporate Corporate/Industrial News Dementia Factiva Filters Financial Services financial vehicles FR:SAN funds general news GlaxoSmithKline GSK GSK.LN health healthcare Healthcare/Life Sciences industrial news investing Investing/Securities life sciences Management Management Moves Medical Conditions medications Mental Disorders Names Neurodegenerative Disease Drugs Pharmaceuticals political Political/General News Private Equity SAN.FR Sanofi securities Senior Level Management specialized drugs Specialized Drugs/Medications SYND trusts Trusts/Funds/Financial Vehicles UK:GSK Venture capital Viehbacher WSJ-PRO-WSJ.com wsjhealth

Add your comment Cancel Reply

You must be logged in to post a comment.